Neimeth International Pharmaceuticals Plc kicked off 2025 with outstanding Q1 results, as surging demand in its pharmaceutical and animal‑health divisions propelled revenue and profit sharply higher.
Neimeth’s earnings jumped to N1.206 billion in Q1 2025, up from N 648 million in the sa
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
